Evidence map›Paper›PMID 41307593›Full record

ArticleBreast cancer research and treatment2025

Breast cancer patients treated at a New York City academic health system during the COVID-19 pandemic in 2021 had delayed presentations and more advanced disease than pre-pandemic cases.

Stephanie Bernik, Tara M Balija, Daniel Kim, Adriano Cuadros, Daniella Jackson, Jean Hee Lee, Niathi Kona, Simran Malhotra, Martina Lopez May, Jaan Nandwani and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Stephanie BernikDivision of Breast Surgery, Department of Surgery, Mount Sinai West - Tisch Cancer Center, 787 11th Avenue, 7th Floor, New York, NY, 10019, USA.
Tara M BalijaDivision of Breast Surgery, Department of Surgery, Mount Sinai West - Tisch Cancer Center, 787 11th Avenue, 7th Floor, New York, NY, 10019, USA. tara.balija@mountsinai.org.
Daniel KimDivision of Breast Surgery, Department of Surgery, Mount Sinai West - Tisch Cancer Center, 787 11th Avenue, 7th Floor, New York, NY, 10019, USA.
Adriano CuadrosIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniella JacksonDivision of Breast Surgery, Department of Surgery, Mount Sinai West - Tisch Cancer Center, 787 11th Avenue, 7th Floor, New York, NY, 10019, USA.
Jean Hee LeeDubin Breast Center Clinical Research Support Unit, Mount Sinai Hospital - Tisch Cancer Center, New York, NY, USA.
Niathi KonaIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Simran MalhotraIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Martina Lopez MayIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Jaan NandwaniIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniella NevidIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Kaothar OladojaIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Borna MohabbatizadehDivision of Breast Surgery, Department of Surgery, Mount Sinai West - Tisch Cancer Center, 787 11th Avenue, 7th Floor, New York, NY, 10019, USA.
Erin MoshierDepartment of Population Health Science Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elisa PortIcahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

NCATS NIH HHS Clinical and Translational Science Awards UL1TR004419
6 · The paper itself

Abstract

purposeThe COVID-19 pandemic was associated with a decrease in the incidence of breast cancers in 2020 and was expected to be associated with advanced stage at presentation in the post-pandemic era. The primary objective of this study is to compare stage at presentation and biological tumor characteristics of breast cancers treated before and after the initial phase of the COVID pandemic.

methodsA retrospective chart review was performed of patients diagnosed with breast cancer within a single New York City health care system between March-August 2019 (pre-pandemic; PP) and March - August 2021 (post- acute phase pandemic; PAP).

resultsThere were 381 patients with breast cancer in the 2019 PP cohort and 558 patients diagnosed in the 2021 PAP cohort. The PAP cohort was more likely to have a larger median tumor size (16 mm vs 12 mm, p < 0.001) and more tumors > 2 cm at surgery (OR 1.48, p = .048). PAP patients were more likely to have node positive disease at surgery (OR 2.54, p = 0.0003), grade 3 tumors (OR 1.29, p = 0.046) and pathologic stage II or III disease at upfront surgery (OR 2.89, p = 0.003). The PAP cohort was also more likely to have > 24 months since their last imaging test (p < 0.001) and less likely to have their breast cancer detected by screening breast MRI (OR .36, p = .016).

conclusionBreast cancer diagnosed in the post-acute pandemic period had a greater odds of having a > 24-month interval since their last screening mammogram and pathologic stage II & III disease than pre-pandemic patients.

Indexed as

Breast NeoplasmsCOVID-19Time-to-TreatmentAdultAgedDelayed DiagnosisFemaleHumansMiddle AgedNeoplasm StagingNew York CityPandemicsRetrospective StudiesSARS-CoV-2Breast CancerBreast Cancer Stage at DiagnosisBreast Cancer Stage at PresentationCancer Delay in DiagnosisCOVID-19Delay in Screening Mammography

Identifiers

PMID41307593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.